On 28–29 April 2026, the GLIOMATCH consortium gathered in Barcelona, Spain, for its fifth consortium meeting, hosted by project partner Sant Joan de Déu Barcelona Children’s Hospital and the Fundació de Recerca Sant Joan de Déu (FSJD).
The meeting brought together researchers, clinicians, data scientists, patient engagement experts, and project management teams from across the consortium to review progress and align activities for the second half of the project. Discussions focused on the advancement of retrospective and prospective clinical studies, tumour microenvironment research, radio-multiomics integration, data management, and future exploitation and valorisation activities.
GLIOMATCH is a Horizon Europe Research and Innovation Action that aims to improve the clinical outcome of adult and paediatric malignant gliomas through tailored immunotherapy treatments supported by spatially resolved radio-multiomics and data-driven precision medicine approaches. The project integrates spatial multiomics, MRI imaging, and advanced computational methods to support personalised treatment stratification and clinical decision-making.
Snapshots from Barcelona
About the Sant Joan de Déu Barcelona Children’s Hospital
The consortium was warmly welcomed by Andrés Morales La Madrid and Cinzia Lavarino from Sant Joan de Déu Barcelona Children’s Hospital and the Fundació de Recerca Sant Joan de Déu (FSJD). Sant Joan de Déu is one of only two standalone children’s hospitals in Spain and one of Europe’s largest paediatric oncology centres, recognised for its specialised expertise in paediatric cancer care and research. During the meeting, consortium members had the opportunity to tour the hospital facilities, including its pioneering central control room, the first of its kind, designed to support the coordination and digital management of hospital operations and patient care. The visit offered valuable insight into the hospital’s innovative infrastructure and its patient-centred approach to healthcare and clinical research.
Sant Joan de Déu plays a key role within GLIOMATCH, particularly through its contribution to the retrospective paediatric clinical study. As one of Europe’s leading paediatric oncology centres and one of only two standalone children’s hospitals in Spain, the institution provides essential expertise in paediatric high-grade glioma research and patient-centred clinical care.
GLIOMATCH partners at the SJD guided visit
Advancing collaboration on key topics for the second half of the GLIOMATCH project
Across the two-day meeting, partners exchanged updates and engaged in strategic discussions covering all major areas of the project, including retrospective and prospective clinical trials, patient recruitment, data integration, spatial multiomics, tumour-host interaction research, MRI-radio-multiomics analysis, ethics and data management, as well as communication, dissemination, and exploitation activities. The sessions provided an important opportunity for consortium members to align on key discussion points and coordinate priorities for the second half of the project, ensuring continued collaboration towards the implementation of GLIOMATCH’s precision immunotherapy approach for adult and paediatric malignant glioma.
The consortium thanks the teams at Sant Joan de Déu Barcelona Children’s Hospital and the Fundació de Recerca Sant Joan de Déu for hosting the meeting and supporting fruitful discussions over the two days.
Snapshots from the meeting sessions
